Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated CS7BL/6 mice

Brain Research

Volumn 728, Issue 2, 1996, Pages 274-276

  Fukuda, Takahiro ^a   Watabe, Kazuhiko ^a   Tanaka, Junichi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bromocriptine; C57BL 6 mouse; L DOPA; MPTP; Parkinsonism

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BROMOCRIPTINE; CARBIDOPA; NEUROPROTECTIVE AGENT; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOCYTOCHEMISTRY; INTRACEREBRAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0030605877     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)00559-8     Document Type: Article

References (12)

1. [1] Diamond, S.G., Markham, C.H., Hoehn, M.M., McDowell, F.H. and Muenter, M.D., Effect of age at onset on progression and mortality in Parkinson's disease, Neurology, 39 (1989) 1187-1190.
2. [2] Fukuda, T., Tanaka, J. and Hasumura, M., Tyrosine hydroxylase-immunohistochemical study in the midbrain of experimental MPTP parkinsonism, Clin. Neurol., 32 (1992) 161-165.
3. [3] Halliday, G.M., Li, Y.W., Blumbergs, P.C., Joh, T.H., Cotton, G.H., Howe, P.R.C., Blessing, W.W. and Geffen, L.B., Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease, Ann. Neurol., 27 (1990) 373-385.
4. [4] Ogawa, N., Asanuma, M., Kondo, Y., Kawada, Y., Yamamoto, M. and Mori, A., Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine, Neurosci. Lett., 171 (1994) 55-58.
5. [5] Ogawa, N., Edamatsu, R., Misukawa, D., Asanuma, M., Kohno, M. and Mori, A., Degeneration of dopaminergic neurons and free radicals: possible participation of levodopa, Adv. Neurol., 60 (1993) 242-250.
6. [6] Ogawa, N., Tanaka, K., Asanuma, M., Kawai, M., Masumizu, T., Kohno, M. and Mori, A., Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro, Brain Res., 657 (1994) 207-213.
7. [7] Spina, M.B. and Cohen, G., Exposure of striatal synaptosomes to L-DOPA elevates levels of oxidized glutathione, J. Pharmacol. Exp. Ther., 247 (1988) 502-507.
8. [8] Spina, M.B. and Cohen, G., Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc. Natl. Acad. Sci. USA, 86 (1989) 1398-1400.
9. [9] Tanaka, M., Sotomatsu, A., Yoshida, T. and Hirai, S., Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron, Neurosci. Lett., 183 (1995) 116-119.
10. [10] Yong, V.W., Perry, T.L. and Krisman, A.A., Depletion of glutathione in brain stem of mice caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment, Neurosci. Lett., 63 (1986) 56-60.
11. [11] Yoshikawa, T., Minamiyama, T., Nito, Y. and Kondo, M., Antioxidant properties of bromocriptine, a dopamine agonist, J. Neurochem., 62 (1994) 1034-1038.
12. [12] Zigmond, M.J., Abercrombie, E.D., Berger, T.W., Grace, A.A. and Stricker, E.M., Compensation after lesions of central dopaminergic neurons: some clinical and basic implications, Trends Neurosci., 13 (1990) 290-295.